← All trials
NCT03503136
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 30, 2018
- Primary completion
- Jun 30, 2024
- Completion date
- Jun 30, 2026
- First posted
- —
- Last posted
- —
- Enrollment
- 632
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Sun Yat-Sen UniversityLead sponsor
- Guangdong Pharmaceutical UniversityCollaborator
- Guangxi Medical UniversityCollaborator
- Soochow UniversityCollaborator
- Sun Yat-Sen UniversityReponsible party - principal investigator
- Sun Yat-Sen UniversityOverall official - principal investigator
- Henan Medical UniversityCollaborator
- Sun Yat-Sen UniversityCollaborator
- Central South UniversityCollaborator
- People's Liberation Army of ChinaCollaborator
- Jilin Provincial Tumor HospitalCollaborator
- Guizhou Medical UniversityCollaborator
- Peking UniversityCollaborator
- First People's Hospital of FoshanCollaborator
- Chinese Academy of Medical SciencesCollaborator
- Guangzhou Medical UniversityCollaborator
- Huazhong University of Science and TechnologyCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.